Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy

Mayo Clin Proc. 1996 Jan;71(1):25-30. doi: 10.4065/71.1.25.


Objective: To characterize chronic necrotizing pulmonary aspergillosis (CNPA) clinically, radio-graphically, and pathologically and to describe its response to treatment.

Material and methods: We present three cases of well-documented CNPA and detail the long-term clinical and pathologic responses to the new antifungal triazole, itraconazole.

Results: Although all three patients had an appreciable clinical response to itraconazole therapy, tissue obtained at the time of operation or autopsy revealed residual CNPA despite 5 to 12 months of treatment. Even though pathologic resolution of the CNPA did not occur, patient prognosis was determined solely by comorbid illness.

Conclusion: Itraconazole seems to be effective in CNPA when used in a suppressive (rather than curative) role in patients with limited life expectancy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antifungal Agents / therapeutic use*
  • Aspergillosis, Allergic Bronchopulmonary / drug therapy*
  • Aspergillosis, Allergic Bronchopulmonary / pathology*
  • Chronic Disease
  • Humans
  • Itraconazole / therapeutic use*
  • Male
  • Middle Aged
  • Necrosis


  • Antifungal Agents
  • Itraconazole